- Molecular NameFinasteride
- SynonymFinasterida [INN-Spanish]; Finasteridum [INN-Latin]
- Weight372.553
- Drugbank_IDDB01216
- ACS_NO98319-26-7
- Show 3D model
- LogP (experiment)3.03
- LogP (predicted, AB/LogP v2.0)2.99
- pkaN/A
- LogD (pH=7, predicted)2.99
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-4.2
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors2
- No.of HBond Acceptors4
- No.of Rotatable Bonds2
- TPSA58.2
- StatusFDA approved
- AdministrationN/A
- PharmacologyA synthetic antiandrogen that acts by inhibiting type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses.
- Absorption_value100.0
- Absorption (description)Finasteride is well absorbed after oral administration
- Caco_2N/A
- Bioavailability63.0
- Protein binding90.0
- Volume of distribution (VD)1.1 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolised in the liver by oxidation to a (17)-monocarboxylic acid metabolite (18.5% of the dose) and ω-hydroxylated finasteride. There is virtually no unchanged drug.
- Half life7.9 h
- ExcretionThe metabolites are excreted in urine (approx. 40%) and faeces (50 to 65%). The drug is widely distributed throughout the body and crosses the blood–brain barrier.
- Urinary Excretion<1
- Clerance2.3 ml/min/kg
- ToxicityDecreased libido, erectile dysfuntion, ejaculation disorders, including decreased volume of ejaculate
- LD50 (rat)N/A
- LD50 (mouse)N/A